3,5-diamino-N-carbamimidoyl-6-(5-methylbenzofuran-2-yl)pyrazine-2-carboxamide

ID: ALA4575138

PubChem CID: 155560933

Max Phase: Preclinical

Molecular Formula: C15H15N7O2

Molecular Weight: 325.33

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1ccc2oc(-c3nc(C(=O)NC(=N)N)c(N)nc3N)cc2c1

Standard InChI:  InChI=1S/C15H15N7O2/c1-6-2-3-8-7(4-6)5-9(24-8)10-12(16)21-13(17)11(20-10)14(23)22-15(18)19/h2-5H,1H3,(H4,16,17,21)(H4,18,19,22,23)

Standard InChI Key:  YYLYKJYHHLLBEG-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
   28.3774  -25.7085    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.3763  -26.5321    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0884  -26.9452    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.8022  -26.5317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.7994  -25.7049    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0866  -25.2996    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.5106  -26.9433    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.6641  -26.9443    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.5056  -25.2936    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.2189  -25.6995    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.5025  -24.4723    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   31.9292  -25.2883    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.6426  -25.6942    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   31.9261  -24.4670    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.6675  -25.3002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.5825  -24.4837    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.9179  -25.6297    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.3686  -25.0234    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.7819  -24.3161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.3734  -23.6082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.5560  -23.6064    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.1487  -24.3184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.5554  -25.0234    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3274  -24.3199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  4  7  1  0
  2  8  1  0
  5  9  1  0
  9 10  1  0
  9 11  2  0
 10 12  1  0
 12 13  1  0
 12 14  2  0
  1 15  1  0
 15 16  1  0
 16 19  1  0
 18 17  1  0
 17 15  2  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 18  1  0
 22 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4575138

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 325.33

Molecular Weight (Monoisotopic): 325.1287

AlogP: 0.99

#Rotatable Bonds: 2

Polar Surface Area: 169.93

Molecular Species: NEUTRAL

HBA: 7

HBD: 5

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.77

CX Basic pKa: 6.12

CX LogP: 1.31

CX LogD: 1.28

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.35

Np Likeness Score: -0.21

References

1. Buckley BJ, Majed H, Aboelela A, Minaei E, Jiang L, Fildes K, Cheung CY, Johnson D, Bachovchin D, Cook GM, Huang M, Ranson M, Kelso MJ..  (2019)  6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.,  29  (24): [PMID:31679971] [10.1016/j.bmcl.2019.126753]

Source

Source(1):

• Scientific Literature